topotecan has been researched along with Experimental Mammary Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herman, TS; Holden, SA; Khandakar, V; Teicher, BA | 1 |
| Tannock, IF; Vukovic, V | 1 |
| Harada, M; Okuno, S; Sakakibara, H; Suzuki, T; Yano, T | 1 |
3 other study(ies) available for topotecan and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Camptothecin; Cell Hypoxia; Cell Survival; Cisplatin; Combined Modality Therapy; Female; Fibrosarcoma; Hydrogen-Ion Concentration; Hyperthermia, Induced; Mammary Neoplasms, Experimental; Mice; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1993 |
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mitoxantrone; Paclitaxel; Topotecan; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cattle; Cysteine Endopeptidases; Dextrans; Dipeptides; Humans; Leucine; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Prodrugs; Rats; Solubility; Species Specificity; Topotecan | 2000 |